Peptide · Approved

Degarelix

A GnRH antagonist (Firmagon) that rapidly lowers testosterone in prostate cancer.

Key facts

  • Also known as: Firmagon
  • Status: Approved
  • Used for: Prostate cancer (GnRH antagonist)
  • Natural counterpart: Blocks the receptor for natural GnRH.
  • Target enzyme / receptor: GnRH receptor (GnRHR) — GPCR (antagonist)
  • Signalling pathway: Blocks GnRH signalling → immediate ↓LH/FSH → ↓testosterone
    In plain terms: Blocks the GnRH receptor to switch off testosterone immediately.
  • Crystal / cryo-EM structure: Available  PDB 7BR3 ↗

Status & safety

This is an approved medicine — prescription-only in most countries. Only use it under a licensed clinician, obtained through a pharmacy.

Research & clinical studies

Explore the biochemistry and clinical evidence for Degarelix — these open live, date-sorted searches, so they always show the latest.

Read research papers on PubMed ↗

Clinical studies (ClinicalTrials.gov) ↗ Google Scholar ↗ Related guide → All peptides & profiles →

Not medical advice. Chemdu is an educational resource and does not sell, prescribe or supply any peptide. Consult a licensed professional about any medicine or supplement.